ArticleDermatology and therapy2026
Real-world Tildrakizumab Effectiveness and Drug Survival: A Cohort Study in the PPD CorEvitas Psoriasis Registry.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTildrakizumab is an interleukin-23 p19 inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis. While clinical trials have demonstrated tildrakizumab efficacy, studies reporting real-world treatment patterns and outcomes for tildrakizumab initiators in North America are needed.
methodsThis analysis included patients who initiated tildrakizumab (October 2018 to April 2024) at or after enrollment in the PPD™ CorEvitas™ Psoriasis Registry, an independent observational study of patients with psoriasis under dermatologic care. Drug survival was analyzed using Kaplan-Meier analysis. Effectiveness was assessed by changes from baseline to 12 (± 3) months in outcomes, including Psoriasis Area Severity Index (PASI), Dermatology Life Quality Index (DLQI), and patient-reported skin pain, itch, and fatigue (scales, 0-100). Results were presented overall and by prior experience with biologic treatments.
resultsThere were 728 tildrakizumab initiators with mean age 58.4, mean PASI 7.7 (standard deviation [SD] 7.3), mean DLQI 7.3 (SD 6.2), and mean patient-reported skin pain, itch, and fatigue scores of 29.7 (SD 32.5), 46.0 (SD 34.4), and 32.3 (SD 29.4), respectively; 47.7% were female, and 383 (52.6%) were biologic-experienced. Restricted mean drug survival for all, biologic-naïve, and biologic-experienced initiators with follow-up was 35.2, 43.3, and 29.5 months, respectively; overall 12-month persistence was 72.8%. Patients with 12 months follow-up (n = 330) had mean improvements from baseline in PASI (4.9, SD 7.0), DLQI (3.9, SD 5.9), and skin pain (mean 13.1, SD 29.9), itch (mean 22.1, SD 34.7), and fatigue (mean 6.7, SD 29.1); 71.3% and 52.9% achieved PASI ≤ 3 and ≤ 1, respectively.
conclusionsBased on clinician- and patient-reported outcomes and a mean drug survival of almost 3 years, tildrakizumab was effective among real-world patients with plaque psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.